According to German researchers, based on laboratory research, they believe they have found a rare but serious cause blood clotting Events among some people who have received Covid-19 Vaccines made by AstraZeneca Plc and Johnson & Johnson.
Researchers, in a study not yet reviewed by experts, said Wednesday that COVID-19 vaccines used by adenovirus carriers – cold viruses used to transmit vaccine materials – carry some of their cargo into the cell nucleus. Where some instructions for making coronavirus proteins may be misread. They suggest that the resulting proteins could potentially cause blood clotting disorders in a small number of recipients.
The number of blood clots associated with the COVID-19 vaccine may be up to 1 in 55,000 blood clots: NACI
Scientists and drug regulators in the United States and Europe are searching for an explanation for the cause of rare but potentially fatal clots with low platelet counts that have led some countries to stop or limit the use of the AstraZeneca and J&J vaccines. Other scientists have proposed competitive theories for clotting conditions.
“As we work with medical professionals and global health officials, we support the continued investigation and analysis of this rare event. We are sharing them. “AstraZeneca declined to comment.
A woman suffers from a rare blood clot disorder following the AstraZeneca vaccine
Researchers at Goethe University Frankfurt and other sites explained in their paper that vaccines use a different technology known as messenger RNA (mRNA), such as those developed by BioNTech SE in partnership with Pfizer Inc. and Moderna Inc. , Provide genetic material The corona virus only increases the virus to the fluids in the cells and not to the nucleus of the cells. “All mRNA-based vaccines must show immune products,” the article said.
Risks of blood clotting: Comparison of COVID-19 vaccines with common drugs, travel and smoking
This article suggests that vaccine manufacturers using adenovirus vectors can modify the spike protein sequence “to prevent adverse reactions in the joints and to increase the safety of these medicinal products.”
View link »
Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of knews.uk and knews.uk does not assume any responsibility or liability for the same.